Drugs
In a significant development in the treatment of prostate cancer, Gloucester Pharmaceuticals, Inc. announced encouraging interim data from its phase 2 clinical study investigating the use of depsipeptide in treating patients with metastatic hormone refractory prostate cancer (HRPC). The data were presented at the American Society of Clinical Oncology (ASCO)
Drugs
Arena Pharmaceuticals, Inc. (ARNA) announced that Ortho-McNeil, Inc., a Johnson & Johnson company, has initiated a phase I clinical trial of APD668, a novel orally administered drug candidate discovered by Arena for the treatment of Type 2 diabetes. This milestone payment triggers a $5 million payment to Arena under its
Drugs
M. D. Anderson Cancer Center, part of the University of Texas, has been awarded a three-year, $4.6 million Specialized Programs of Research Excellence (SPORE) grant from the U.S. National Cancer Institute for breast cancer research. This is the institution's 10th such grant since 1996, making it
Drugs
A novel ATP-based Src family kinase inhibitor, AP23846, has been found to exhibit potent anti-cancer properties, particularly in tumor progression and metastasis. According to a study published in Molecular Cancer Therapeutics, AP23846 inhibited angiogenic protein in tumor cells, blocking the production of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8)
Drugs
Researchers in France, Italy, and the United States have published groundbreaking studies that may lead to the development of more effective cancer therapies. The studies, published in reputable scientific journals, focus on novel ways to combat cancer, including the use of small interfering RNAs (siRNAs) and cyclooxygenase-2 (COX-2) inhibitors. Key
Drugs
Recent research from the People's Republic of China has shed light on the role of MGr1-antigen in regulating tumor multidrug resistance (MDR) in gastric cancer cells. The study, published in the journal Tumor Biology, found that MGr1-Ag promotes the MDR phenotype of gastric cancer cells, decreases intracellular drug
Drugs
Recent research from Japan, the United States, and Italy has made significant progress in the development of anti-angiogenic therapies for cancer. These studies have highlighted the potential of targeting vascular endothelial growth factor (VEGF) receptors to inhibit tumor growth and metastasis. In Japan, researchers at Taisho Pharmaceutical Co. Ltd. have
Drugs
Researchers in the United States have made significant advancements in cancer therapy using targeted agents, as outlined in three studies published in various medical journals. These studies explore the efficacy and tolerability of combining bevacizumab and erlotinib, the antitumor activity of HER-2 inhibitors, and the antiangiogenic properties of cetuximab. The
Drugs
Low-dose estrogen therapy, paired with fulvestrant, is being proposed as a promising strategy to maintain tumor control in breast cancer patients whose tumors have become resistant to traditional hormone therapies. Scientists in the United States have discovered that exhaustive antihormonal therapy can lead to two phases of resistance, with estrogen
Drugs
Pediatric patients with sarcoma who received epirubicin as part of a study in Germany showed low levels of cardiotoxicity, according to researchers. The study, which included 172 patients between the ages of 2 and 18, found that the incidence of clinically manifest cardiomyopathy was 0% in patients treated with epirubicin,
Drugs
Recent research from Ireland has shed light on the potential of vitamin C to enhance the effectiveness of chemotherapy in treating esophageal cancer. The study, conducted by M.M.M. Abdellatif and colleagues at St. James Hospital, found that vitamin C can inhibit the activation of certain transcription factors, thereby
Drugs
A recent surge in oncology research from the United States and Turkey has shed light on novel approaches to treating breast cancer. Curcumin, a compound found in turmeric, has been shown to prevent breast cancer metastasis to the lungs by potentiating chemotherapy. Additionally, heparanase, an enzyme that promotes tumor growth
